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CAN A REUSABLE SURGICAL FACE MASK BRING HEALTH
ECONOMIC AND ECOLOGICAL BENEFIT TO A HEALTH




Objectives: Triggered by the prevention of the spread of COVID-19, two types of
surgical masks became available to health systems: disposable and reusable. The
purpose of our study was to assess whether there is an economic and ecological
difference in the application of reusable surgical masks versus disposable surgical
masks. Methods: We developed a de novo model that took into account the char-
acteristics of the Belgian hospital market: 52000 beds, 2 healthcare FTE per bed, and
the ability to rely on a disposable surgical mask versus a reusable surgical mask that
could be reused up to 35 times. We considered the following costs: product cost,
medical waste, logistics, and washing. Results: From an ecological and supply chain
point of view the implementation of reusable masks could result in a reduction of
92.000 Kilograms of medical waste and 90% less warehouse space required. From an
economic point of view when the cost per disposable mask goes above 0.10 V per
unit, material economic savings were identified. As from 0.15V per unit of disposable
masks, economic savings varied between 1.5 million and 10 million V per year. The
critical factors that define the possible economic savings include: the base price of
the reusable mask, the cost of washing, as well as the number of times that a mask
could be reused. Conclusions: Health systems may benefit from the inclusion of
reusable surgical masks versus disposable surgical masks. This benefit is fourfold.
Gains could be achieved from an ecological, supply chain risk mitigation, ware-
housing optimization, as well as from an economic perspective.
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Objectives: Efficiency analyses of health systems are often limited to hospital ap-
plications or macroeconomic evaluations considering a single production process.
This application using a two-stage prevention and cure network perspective high-
lights nonparametric frontier estimations more coherently with the current COVID-
19 pandemic scenario. Methods: This two-stage Data Envelopment Analysis meth-
odology estimates cost efficiencies of preventing an increasing propagation of
COVID-19 using the Federal Government COVID-19 expenditures as input and the
inverse rate of cases as output (standardized by population) in the first stage. The
second stage for the technical efficiency (cure model) has the number of ICUs,
ventilators and medical staff (nurses, assistants and physicians) as input and success
rate (the difference between the number of infected and deaths) as output.
Results: Two efficient states on both prevention and cure models (Acre and Ror-
aima). Pernambuco is deemed efficient in preventing COVID-19 (3 states total), and
São Paulo, Mato Grosso, Amapá, Santa Catarina and Rio Grande do Sul (7 states) in
cure. About 1400 ICU admissions, 590 ventilators and more than 100 thousand
medical staff can be spared directed by best practices from these seven efficient
states. The most inefficient states in preventing the pandemic are São Paulo (0.028),
Bahia (0.076), Rio Grande do Sul (0.087) and Paraná (0.098), also reporting low social
isolation. The most inefficient states in cure are Rio de Janeiro (0.231), Pernambuco
(0.277), and Rio Grande do Norte (0.439). Conclusions: The proposed methodology
offers an interesting framework combining both public health perspectives as re-
sponses to the COVID-19 pandemic. Brief comments can be made on Pernambuco’s
mapping technologies available for the general population; the cooperation between
the government and NGOs in Roraima for providing EPIs, tests, food and hygiene
items for indigenous districts (reducing potential propagations without expanding
governments expenditures); and Acre’s campaigns for basic hygiene, and pandemic
control.
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Objectives: We aimed to estimate the direct medical costs due to COVID-19 hospi-
talizations in Colombia. Methods: We carried out a retrospective cost-of-illness
study of COVID-19 confirmed patients treated at health facilities in 23 municipalities
of 12 Colombian departments. We included third payer perspective: Colombianhealth system. Medical records are stored in a hospital management database that
details the consumptions of each hospitalized patient, inventorying the health
technology consumption of the patients selected for analysis. Patients were hospi-
talized fromMarch 15 and May 29, 2020. Absolute and relative frequencies, averages,
medians, and interquartile ranges (IQR) were used to characterize the population and
estimate the direct medical costs. We stratified the cost analysis by sex, age groups,
comorbidities, and type of hospitalization (general ward and intensive care unit -
ICU). Costs were reported in American dollars (USD) (1USD = 3,903 Colombian pesos
- COP). Results: We studied 113 patients hospitalized by COVID-19, 51.3% men. On
average, the hospital length of stay for COVID-19 hospitalized patient was 7,3 (6 6,2)
days with a median cost of $1,688 (IQR 788-2,523). In women, the median direct
medical cost of hospitalization was $1,328 (IQR $463-$2,098), while in men was 1.4
times greater. Being 60 years of age or older triggers hospitalization costs almost
twice as high as those under this age ($1,813 vs. $2,994), and when the cost is
compared by type of hospitalization, this difference is more than three times (ICU:
4,118; general ward: $1,312). Conclusions: Costs incurred by COVID-19 patients
generate a considerable impact for health system. Other studies in Colombia re-
ported significantly lower hospitalization costs for infections such as influenza ($ 484
general ward and 3,044 in ICU). However, the costs of our study were much lower
than those reported in COVID-19 in other countries.
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Objectives: For pediatric patients deemed ultra-rapid metabolizers (UMs), genetic
variability in CYP2D6 increases codeine’s risk of respiratory depression and death. As
the cost of pharmacogenomics (PGx) testing decreases and the sensitivity and
specificity of PGx testing improves, pain management may benefit from greater PGx-
testing adoption. The objective of this study is to determine the cost-effectiveness of
PGx testing to guide short-term post-surgical codeine therapy in pediatric patients.
Methods: We developed a TreeAge-based decision analytical model to compare
opioid analgesia with and without PGx testing using a payer’s perspective. For PGx-
guided opioid analgesia, we restricted the use of codeine to non-UMs only and
considered alternative opioids among patients deemed UMs. We measured the
effectiveness as (i) reduction in the hospital length of stay (LOS) due to opioid-
induced adverse drug reactions (ADRs) related to the respiratory system, and (ii)
averting respiratory depression, a severe opioid-induced ADR. Model parameters
were taken from published literature. Results: Compared to non-PGx testing, PGx
testing resulted in approximately 0.0441 fewer LOS days with an incremental cost of
$362, resulting in TreeAge reported incremental cost-effectiveness ratio (ICER) of
$8,214. PGx testing also resulted in approximately 0.0055 fewer respiratory
depression events with an incremental cost of $404 compared to non-PGx testing.
The TreeAge reported ICER value was estimated at $73,177 to avert a severe respi-
ratory depression event with PGx testing. The results were robust in probabilistic
sensitivity analyses for LOS outcomes. However, for the respiratory depression
outcome, 71.8% of iterations resulted in an ICER value exceeding the common
$50,000 willingness to pay threshold. Conclusions: This analysis suggested that PGx
guided opioid analgesia with codeine is a cost-effective strategy for pain manage-
ment in pediatric patients. As the availability and cost of PGx testing improve, pol-
icymakers may want to reconsider the benefit of PGx guided pain management,
including codeine.
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Objectives: Budget Impact Models (BIMs) are used to estimate the financial impact
to a health plan of adding a new drug. ISPOR’s Guidelines for BIMs call for addressing
the costs associated with current relevant therapies and new therapies. The US
Medicare Part D benefit structure spreads liability across stakeholders: (1) private
Part D insurers, (2) patients, (3) federal government, and (4) brand manufacturers.
Stakeholder liability also changes as patient pharmacy spending increases and is
based on the patient’s income status. Therefore, traditional assumptions used in
most BIMs (e.g. 10% coinsurance / 90% plan liability; “simplistic approach”) will
produce inaccurate results for Medicare Part D stakeholders. A more refined meth-
odology using Part D claims should be utilized (“claims-based approach”). Meth-
ods: Medicare Part D claims for patients were adjusted for new Brand Drug A and
applied the Medicare Part D benefit structure. This simulation added Drug A scripts
without replacing other drugs. Each Drug A price was simulated as price impacts
patients’ total pharmacy spend. Assumptions used in all scenarios: 0% rebate, 0%
discount, 12 scripts, 10% coinsurance (simplistic approach), and the 2021 Part D
